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Wound problems in hip arthroplasty following introduction of dabigatran  
2 
 
Abstract 
NICE guidelines have stated that patients undergoing elective hip surgery are at 
increased risk for venous thromboembolic events (VTE) following surgery and 
have recommended thromboprophylaxis for 28-35 days1, 2.  However the studies 
looking at the new direct thrombin inhibitors have only looked at major bleeding.  
We prospectively looked at wound discharge in patients who underwent hip 
arthroplasty and were given dabigatran postoperatively between March 2010 and 
April 2010 (n=56).  We retrospectively compared these results to a matched 
group of patients who underwent similar operations six months earlier when all 
patients were given dalteparin routinely postoperatively until discharge, and 
discharged home on 150mg aspirin daily for 6 weeks (n=67).  Wound discharge 
after 5 days was significantly higher in the patients taking dabigatran (32% 
dabigatran n=18, 10% dalteparin n=17, p=0.003) and our rate of delayed 
discharges due to wound discharge significantly increased from 7% in the 
dalteparin group (n=5) to 27% for dabigatran (n=15, p=0.004).  Patients who 
received dabigatran were more than five times as likely to return to theatre with a 
wound complication as those who received dalteparin (7% dabigatran n=4, vs. 
1% dalteparin n=1), however, this was not statistically significant (p=0.18).  The 
significantly higher wound discharge and return to theatre rates demonstrated in 
this study have meant that we have changed our practice to administering 
dalteparin until the wound is dry and then starting dabigatran. Our study 
demonstrates the need for further clinical studies regarding wound discharge and 
dabigatran.    
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Wound problems following hip arthroplasty before and after the 
introduction of dabigatran 
 
NICE guidelines state that patients undergoing elective hip surgery are at 
increased risk for venous thromboembolic events (VTE) following surgery and 
have recommended thromboprophylaxis for 28-35 days1, 2. They state patients 
can be given unfractionated heparin, low molecular weight heparins or the newer 
direct thrombin inhibitors.  The new drugs have the advantage of being orally 
administered and have no need for coagulation monitoring3.  However, studies 
looking at their efficacy have only looked at major bleeding.  Wound discharge 
and the subsequent need for further operations and delays in discharge have not 
been examined.  This study aims to report the effects of dabigatran on wound 
complications, infections and return to theatre in patients undergoing primary and 
revision total hip arthroplasty and hip resurfacing. 
 
Methods 
The study was conducted at a District General Hospital which operates on 
around 1350 joints per year. Six consultants and four associate specialists 
operated on patients during this time.   
 
For the study group (group 1), we prospectively collected data on how long the 
wound took to dry in patients who underwent total hip arthroplasty, revision hip 
arthroplasty and hip resurfacings and were given dabigatran postoperatively 
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between March 2010 and April 2010 (Table 1). During this period, patients 
received a half dose (75 mg or 110mg tablet) on the day of surgery followed by a 
full dose (2x75mg or 2x110mg) on each subsequent day.  The reduced dose was 
given to patients who were over 75 years old, had moderate renal impairment 
(creatinine clearance 30-50 ml/hr) or were taking amiodarone or verapamil as per 
the manufacturer’s guidelines.   
 
The control group (group 2) was a retrospectively matched group of patients who 
underwent the same operations by the same group of surgeons six months 
earlier between October 2009 and November 2009. During this period, all 
patients were routinely given dalteparin 5000 units subcutaneously from day one 
postoperatively until discharge and then 150mg aspirin daily for 6 weeks post 
discharge.   
 
The average length of stay in our unit is 5 days.  Patients are not discharged until 
their wounds are dry so the notes of the patients who stayed for longer than 5 
days were examined. Those patients who were delayed for discharge due to 
wound discharge were documented.  
 
All wounds were dressed with a Cosmopore dressing. These were changed 
when they were soiled or after 3 days.  All patients wore anti-thromboembolic 
stockings for six weeks after surgery, received three doses of intravenous 
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prophylactic antibiotics and were encouraged to mobilise early in the post-
operative period. Patients using warfarin were excluded from the study.   
 
All patients were followed up for six months by searching the hospital database 
to ascertain if there had been any further admissions or appointments after their 
6 week appointment for wound problems. 
 
Results 
 
The demographic patient data are given in Table 1. The age range, median age 
and male to female ratios were similar in both groups.  Group 1 had a higher 
proportion of total hip replacements (95 %, n=53) compared with group 2 (87%, 
n=58) and there were no hip resurfacings in group 1 but this was not statistically 
significant.  Group 1 had fewer operations done by consultants than group 2 
(30% group 1 n=17, to 57% group 2 n=38) although the majority were performed 
by associate specialists (66% group 1 n=39, 37% group 2 n=29), which was 
statistically significant.  The wound closure methods were similar in both groups 
(Figure 1).   
 
The endpoints and complications are shown in Figure 2 and Table 2 respectively. 
There was significantly more wound discharge after 5 days in the patients taking 
dabigatran (32% dabigatran n=18, 10% dalteparin n=7, p=0.003) and the rate of 
delayed discharges due to wound discharge significantly increased from 7% in 
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the dalteparin group (n=5) to 27% for dabigatran (n=15, p=0.004).  Patients who 
received dabigatran were more than five times as likely to return to theatre with a 
wound complication as those who received dalteparin (7% dabigatran n=4, vs. 
1% dalteparin n=1), however, this was not statistically significant (p=0.18).  
During the first 4 weeks of the trial, 3 people were taken to surgery for wound 
washout and one of these was discharged on intravenous antibiotics.   
 
Two patients in the dabigatran group were readmitted after discharge with a 
leaking wound which responded to intravenous antibiotics and one patient from 
this group was admitted five months after the initial operation for washout of an 
old haematoma around the hip replacement.   
 
Discussion  
 
Historically the risk of fatal PE was thought to be as high as 3%4.  Now with 
improved anaesthesia, surgical technique and rehabilitation the risk is thought to 
be less than 0.5%5-10.  There is an increased risk of VTE for some time after THR 
(DVT at mean of 22.5 days 6-37) and TKR (mean 5 days post op, 3-8)5, 7, 11, 12. 
Dahl et al stated that using thromboprophylaxis for 35 days instead of 7 days will 
nearly halve the rate of post operative venographically detected DVT1, 13and this 
has been recommended by the American College of Chest Physician (ACCP) 
guidelines 4. The NICE guidelines to reduce venous thromboembolic events 
following surgery have been developed with these factors in mind.   
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Surgeons in the USA historically have used warfarin but this has problems with a 
narrow therapeutic index, the need for regular monitoring and frequent dose 
adjustments.  European surgeons use low-molecular weight heparin (LMWH) but 
these need subcutaneous administration daily which may be difficult in an 
outpatient setting especially if required after early discharge5, 15.  Dabigatran 
etexilate is a prodrug of dabigatran, a potent non-peptidic small molecule that 
specifically and reversibly inhibits both free and clot bound thrombin by binding to 
the active site of the thrombin molecule16-19.  It has a rapid onset of action and 
estimated half-lives of 8–10 hours and 14–17 hours with single- and multiple-
dose administration, respectively20. It does not need to have daily monitoring and 
as it is an oral tablet it is thought to have fewer problems with compliance than 
subcutaneous LMWH.   
 
However some studies have shown that dabigatran caused more major bleeding 
in hips and more serious adverse events than enoxaparin with a higher rate of 
any and major VTE3, 21. Most of the studies are inconsistent in their reporting of 
major bleeding (defined as death related bleeding, bleeding into a critical organ 
and bleeding requiring transfusion of more than 2 units) but did not include 
bleeding that warranted a second surgery to stop bleeding2, 15. The studies did 
not look at wound complications.   
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Wound infection carries costs to the individual and the NHS in terms of longer 
hospital stays, prolonged antibiotic courses and the need for more surgery with 
costlier implants22, 23.  Deep infection in hip prostheses is often associated with a 
discharging postoperative wound and early wound complications such as a 
draining haematoma carry a higher risk of developing late deep infection than 
those which healed uneventfully24-26.  Even if the wound discharge itself does not 
cause the infection, the increased use of blood transfusion is associated with an 
increased risk of infection27.   
 
Our results show that the wound discharge after 5 days was highest in patients 
taking dabigatran (32% group 1, 10% group 2) which was statistically significant.  
Following the introduction of dabigatran, our rate of delayed discharges due to 
wound discharge rate went up from 7% in patients on dalteparin to 27% in 
patients on dabigatran, again statistically significant.   
 
Patients who received dabigatran were more than five times as likely to return to 
theatre with a wound complication as those who received dalteparin (7% vs 1%) 
although this was not statistically significant.  One patient on dabigatran was 
discharged on six weeks of intravenous antibiotics as his wound continued to 
discharge after 3 washouts.  No patients in group 2 were discharged on 
intravenous antibiotics.  Two patients treated with dabigatran were readmitted 
after discharge with a leaking wound which responded to intravenous antibiotics 
and one patient treated with dabigatran was admitted five months after the initial 
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operation for washout of an old haematoma around the hip replacement.  There 
were no such admissions for any of the patients in group 2.   Surgery needed 
either during the initial admission or on a subsequent admission was not 
statistically significant but we feel this is a reflection of the small numbers in our 
studies.   
 
The number of patients staying over 5 days was statistically significantly higher in 
group 1 compared to group 2.  Our results also show that the proportion of 
patients undergoing a revision total hip arthroplasty was higher in group 2 
compared to group 1 (group 1 – 5%, group 2 – 7%).  As revision hips tend to take 
longer to be discharged due to the increased complexity of their surgery, we feel 
that this difference would not account for the difference in discharge rates.  The 
proportion of consultants who performed the operation was higher in group 2 
compared to group 1 and this may have contributed to the lower wound 
discharge rate in group 2.  However, the majority of operations in group 2 were 
performed by our associate specialty surgeons who are experienced surgeons. 
 
Group 2 used staples more often as a closure method than group 1 (Group 1 n= 
1, group 2 n= 15, Figure 1).  However this was the group with fewer problems 
with wound discharge.  A meta-analysis in the BMJ stated that staple usage was 
associated with an increased rate of superficial wound infection so we feel this 
change would not account for the difference in wound discharge and infection 
rates 28. 
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Although the comparative data set was collected retrospectively, we are 
confident that it reflects an accurate representation of our normal operative 
practice in this department.  There were multiple surgeons in both the groups but 
they did not change between the two groups and all other local factors (antibiotic 
prophylaxis used, patients all going to a single, MRSA free ward post-operatively) 
remained the same.  We are aware that the study size is small but we feel that 
the problems with the wound discharge, delayed discharge and need for further 
operative intervention in our patients who were started on dabigatran prior to 
their wound drying up meant we were unable to continue with this practice.  After 
3 weeks of dabigatran being given postoperatively, we felt the wound discharge 
and return to theatre rates were too high to continue and changed our practice to 
5000 units of subcutaneous dalteparin until the wound was dry and then the 
patients were started on the manufacturer recommended dose of dabigatran and 
continued for 35 days of anticoagulation in total.  We collected prospective data 
on these patients (see table 3 for patient demographics) and no further patients 
in the next 4 weeks needed their wounds washed out.   
 
These findings were similar to a number of presentations at the recent 2011 
British Hip Society meeting where the newer direct thrombin inhibitors were 
shown to have prolonged oozing, an increased number of wound problems and 
an increase in the overall return to theatre rate compared to aspirin or heparin29-
32. 
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Conclusion 
 
Based on this study we no longer prescribe dabigatran from the day of surgery 
but rather prescribe dalteparin until the wound is dry postoperatively and then the 
patient is discharged home on dabigatran.  Our study demonstrates the need for 
further clinical studies regarding wound discharge and dabigatran.   
 
Statistical assistance given by Sarah L Whitehouse Orthopaedic Research Unit, 
The Prince Charles Hospital, Chermside, Australia 
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Tables and figures: 
 
Table 1 - Demographics 
 
 
Group 1 
(Dabigatran) 
Group 2 
(Dalteparin) 
p-value 
Number 56 67  
Female:Male 32:24 39:28 1.0 
Age Range (years) 
38-90, median 
70 
31-94, 
median 70 
0.88 
Operation: THR 53 58  
 Revision THR 3 5 0.15 
 Hip Resurfacing 0 4  
Surgeon grade: Consultant/ 
Associate Specialist 17/39 38/29 
0.04* 
 
* significant at 5% 
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Table 2 – Endpoints examined for each group 
 
 Group 1 Group 2 p-value 
Total number 56 67  
Median length of stay (days)  
7.0 (range 
3-32, IQR 5) 
5.0 (range 
1-60, IQR 3) 
0.002* 
Wound discharge after 5 days (%) 18 (32%) 7 (10%) 0.003* 
Patient discharge delayed due to 
wound discharge (%) 
15 (27%) 5 (7%) 0.004* 
Surgery needed for wound whilst 
either inpatient or post discharge (%) 
4 (7%) 1 (1%) 0.18 
 - whilst inpatient (%) 3 (5%) 1 (1%) 0.23 
  - post discharge (%) 1 (2%) 0 (0%) 0.46 
 
IQR = interquartile range 
*significant at 5%  
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Table 3 – Demographics of Group 3 
 
 
Group 3 (Dalteparin until 
wound dry then Dabigatran) 
Number 19 
Female:Male 12:7 
Age Range (years) 48-89, median 73 
Operation: THR 15 
 Revision THR 4 
 Hip Resurfacing 0 
Surgeon grade: Consultant/Associate 
Specialist 11:7 
Median length of stay (days)  7 (range 5-22, IQR=3) 
Wound discharge after 5 days (%) 3 (15%) 
Patient discharge delayed due to wound 
discharge (%) 3 (15%) 
Surgery needed for wound whilst either 
inpatient or post discharge (%) 0 
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Figure 1 – Wound closure methods 
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Figure 2 – Complications 
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